[ad_1]
The CEO of Dendreon and the CEO of GE Ventures explain.
Time
Immunotherapy has helped patients with an aggressive form of breast cancer live longer, a study released on Saturday said.(Photo: Getty Images / iStockphoto)
Immunotherapy, a treatment used to strengthen the body's immune system, has allowed some patients with an aggressive form of breast cancer to live longer, according to a study.
This treatment is the first immunotherapy to improve outcomes in patients with triple negative breast cancer, said Peter Schmid, author of the study and clinical director of St. Bartholomew's Breast Cancer Center in London.
The results were presented at the 2018 Congress of the European Society of Medical Oncology held Saturday and published in the New England Journal of Medicine.
The researchers conducted a clinical trial involving more than 900 patients with triple-negative metastatic breast cancer and having not received prior treatment for metastatic disease.
Patients receiving a combination of standard chemotherapy and atezolizumab antibodies reduced by 20% the risk of death or worsening of the disease.
According to the researchers, the survival rate of patients with triple metastatic breast cancer, a rare form of cancer often affecting younger women, is 12 to 15 months.
Schmid said the treatment "will change the way triple negative breast cancer is treated".
"This combination should become a new treatment option for patients with triple negative metastatic breast cancer," Schmid said in a statement.
Many studies have shown how immune therapy can fight many cancers, including malignant brain tumors and lung cancer.
More:Immune therapies improve cancer treatment
Follow Brett Molina on Twitter: @ brettmolina23.
Read or share this story: https://www.usatoday.com/story/news/nation-now/2018/10/22/triple-negative-breast-cancer-immunotherapy-success-touted-study/1725410002/
[ad_2]
Source link
